Piccoleto II: my interview during JIM 2020 on the 1 year outcome of the Piccoleto II study

https://www.radcliffecardiology.com/JIM-2020-PICCOLETO-II-trial-Bernardo-Cortese

1. What was the PICCOLETO II study design and what did it aim to assess?
2. What are the key outcomes and how do they compare to studies such as BASKET-SMALL II?
3. Were there limitations with PICCOLETO II?
4. In your opinion, how should PICCOLETO II influence practice?
5. What questions remain unanswered that require further research?

Sirolimus: my interview during JIM 2020 on the current status of research concerning Sirolimus-coated balloons for coronary use

https://www.radcliffecardiology.com/JIM-2020-Sirolimus-DCB-Bernardo-Cortese

1. Why are Sirolimus DCBs needed as a technology?
2. How does the Sirolimus coating work?
3. What data supports there use in comparison to other DCBs?
4. When are you using DCBs in your practice?
5. What further research is required to validate sirolimus DCBs as the coating of choice?

Is paclitaxel associated with higher mortality? The DCB in periphery conundrum: my perspective

About one year ago, a metanalysis conducted by Dr. Katsanos and Coll. showed an increase in mortality following the use of paclitaxel-coated balloons / stents when used for femoro-popliteal PTA. The whole sector was evidently shocked as a result to this metanalysis, and many actions (some of them absolutely unjustified) have been taken since then.

After one year, after a necessary cooling off period and further analyses, it is time for me to take a clear position on the matter.

Therefore, we are presenting our point of view regarding the topic, as expressed in some published editorials.

Today we are presenting the last one:

“Mortality Increase and Paclitaxil-Coated Device Use” December 2019

Is paclitaxel associated with higher mortality? The DCB in periphery conundrum: my perspective

About one year ago, a metanalysis conducted by Dr. Katsanos and Coll. showed an increase in mortality following the use of paclitaxel-coated balloons / stents when used for femoro-popliteal PTA. The whole sector was evidently shocked as a result to this metanalysis, and many actions (some of them absolutely unjustified) have been taken since then.

After one year, after a necessary cooling off period and further analyses, it is time for me to take a clear position on the matter.

Therefore, we are presenting our point of view regarding the topic, as expressed in some published editorials.

Today we are presenting the following one:

“The hypothesis of an increased mortality following paclitaxel coated device use in peripheral vascular interventions (and the emerging era of meta-analysis based evidence)” 22.10.19